Llovet, Josep M.; Yen, Chia-Jui; Finn, Richard S. et al.
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 37. H. 15. 2019
Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui et al.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY. Bd. 20. H. 2. 2019 S. 282-296
Zhu, Andrew X.; Finn, Richard S.; Galle, Peter R. et al.
Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoproteinLANCET ONCOLOGY. Bd. 20. H. 4. 2019 S. E191-E191
Llovet, J.; Kudo, M.; Kang, Y-K. et al.
Ramucirumab in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha fetoprotein (AFP): An exposure-response analysisANNALS OF ONCOLOGY. Bd. 30. 2019 S. 293-+
Ziebart, Alexander; Schaefer, Moritz M.; Thomas, Rainer et al.
Random allogeneic blood transfusion in pigs: characterisation of a novel experimental modelPEERJ. Bd. 7. 2019
Strieth, Sebastian; Ernst, Benjamin P.; Both, Ina et al.
Randomized controlled single-blinded clinical trial of functional voice outcome after vascular targeting KTP laser microsurgery of early laryngeal cancerHEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK. Bd. 41. H. 4. 2019 S. 899-907
Kim, Yong Ook; Park, Kyoung-Sook; Schuessler, Christoph et al.
RAPIDLY PROGRESSIVE, POLYCLONAL ORTHOTOPIC HEPATOCELLULAR CARCINOMA (HCC) IN MDR2 (abcb4) KNOCKOUT MICE TREATED WITH DIETHYLNITROSAMINE AND PHENOBARBITALHEPATOLOGY. Bd. 70. 2019 S. 1208A-1209A
Goepfert, Katrin; Dinsart, Christiane; Rommelaere, Jean et al.
Rational Combination of Parvovirus H1 With CTLA-4 and PD-1 Checkpoint Inhibitors Dampens the Tumor Induced Immune SilencingFRONTIERS IN ONCOLOGY. Bd. 9. 2019
Salwender, Hans; Bertsch, Uta; Weisel, Katja et al.
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaBMC CANCER. Bd. 19. 2019
Habibi, Yasamin; Habibi, Edriss; Al-Nawas, Bilal
Re-exposure in cone beam CT of the dentomaxillofacial region: a retrospective studyDENTOMAXILLOFACIAL RADIOLOGY. Bd. 48. H. 3. 2019